The Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein of the prostate secretory acinar epithelium that is upregulated in prostate cancer (PC) and known from its use in diagnostics and targeted therapy in metastatic PC [1–4]. Here, FOLH1 is linked to pachyonychia congenita.